Hyung L. Kim, MD
Homer and Gloria Harvey Family Chair in Urologic Oncology in honor of Stuart Friedman, MD
Director, Academic Urology Program
Co-Medical Director, Urologic Oncology Center
Associate Director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute
Associate Director, Urology Residency Training Program
Professor, Surgery
Clinical Office
West Medical Office Tower, Suite 1070W
8635 W 3rd St
Los Angeles, CA
90048
Phone:
310-423-4700
Fax:
310-423-4711
Hyung L. Kim, MD
Homer and Gloria Harvey Family Chair in Urologic Oncology in honor of Stuart Friedman, MD
Director, Academic Urology Program
Co-Medical Director, Urologic Oncology Center
Associate Director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute
Associate Director, Urology Residency Training Program
Professor, Surgery
Specialty
- Urology
Clinical Areas
Adrenal Gland Cancers
Adrenal Gland Disorders
Adrenalectomy (Adrenal Gland Removal)
Bladder Cancers
Cystectomy (Urinary Bladder Removal)
Kidney Cancers
Neobladder Surgery / Surgeries
Nephrectomy
Pheochromocytoma
Prostate Cancers
Robotic Cystectomy
Robotic Prostatectomy
Testicular Cancers
Ureteropelvic Junction Obstruction (UPJ)
Research Profile
Hyung L. Kim, MD, is director of the Cedars-Sinai Academic Urology Program and associate director of Surgical Research in the Samuel Oschin Comprehensive Cancer Center. He has two professional passions. As a practicing urologic oncologist, Kim is devoted to promoting the physical and emotional health of his patients with cancers of the kidney, testis, prostate and bladder. His training includes fellowships in urologic oncology and minimally invasive surgery. He routinely provides treatments and second opinions for complex and difficult urologic cancer cases. Kim's second area of professional passion is his laboratory research, which has two areas of focus. The first area involves developing novel immune therapies for cancers. His lab is investigating the immune modulating effects of molecularly targeted therapies administered in combination with cancer vaccines. Heat shock protein-based cancer vaccines are used as model vaccines. Therapeutic goals include generating high-quality memory T cells and suppressing regulatory T cells. Kim's research also focuses on discovery and validation of clinically useful biomarkers for patients with urologic cancers. His laboratory has been developing new technology for generating multimarker expression profiles using archival tumors. His clinical work and research are highly complementary. Kim can offer his patients leading-edge treatment approaches, and the most challenging patient cases provide ideas and inspiration for his research.
Education
- Medical School: University of Chicago Pritzker School of Medicine, 1996
- Internship: University of Chicago Medical Center, 1998
- Residency: University of Chicago Hospitals, 2002
- Fellowship: UCLA David Geffen School of Medicine, 2003
- Fellowship: UCLA David Geffen School of Medicine, 2004
Cedars-Sinai Affiliations
Awards & Activities
- Cancer and Leukemia Group B Junior Faculty Research Award
- Endowment, Medallion Chair in Urology
- American Urologic Association Surgeon Scientist Award
- Edwin Beer Award
Publications
Click here for a list of peer-reviewed publications.
- Li P, Conley A, Zhang H, Kim HL. Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq. BMC Genomics. 2014;15:1087.
- Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT, Kim HL. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859-864.
- Kim HL, Puymon MR, Qin, M, Guru K, Mohler JL. A method for using life tables to estimate lifetime risk for prostate cancer death. J Natl Compr Canc Netw. 2010;8(2):148-154.
Languages Spoken
English / Korean
Make an Appointment